• 1
    Lundberg IE. The role of cytokines, chemokines, and adhesion molecules in the pathogenesis of idiopathic inflammatory myopathies. Curr Rheumatol Rep 2000;2:21624.
  • 2
    Fedczyna TO, Lutz J, Pachman LM. Expression of TNFα by muscle fibers in biopsies from children with untreated juvenile dermatomyositis: association with the TNFα-308A allele. Clin Immunol 2001;110:2369.
  • 3
    Pachman LM, Liotta-Davis MR, Hong DK, Kinsella TR, Mendez EP, Kinder JM, et al. TNFα-308A allele in juvenile dermatomyositis: association with increased production of tumor necrosis factor α, disease duration, and pathologic calcifications. Arthritis Rheum 2000;43:236877.
  • 4
    Huber AM, Giannini EH, Bowyer SL, Kim S, Lang B, Lindsley CB, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children's Arthritis and Rheumatology Research Alliance consensus conference. Arthritis Care Res (Hoboken) 2010;62:21925.
  • 5
    Efthimious P, Schwartzman S, Kagen LJ. Possible role for tumor necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 2006;65:12336.
  • 6
    Hengstman GJ, van den Hoogen FH, Barrera P, Netea MG, Pieterse A, van de Putte LB, et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor α: preliminary observations. Eur Neurol 2003;50:105.
  • 7
    Riley P, McCann LJ, Maillard SM, Woo P, Murray KJ, Pilkington CA. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 2008;47:88780.
  • 8
    Muscle Study Group.A randomized, pilot trail of etanercept in dermatomyositis. Ann Neurol 2011;70:42736.
  • 9
    Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:3447.
  • 10
    Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975;292:4037.
  • 11
    Bode RK, Klein-Gitelman MS, Miller ML, Lechman TS, Pachman LM. Disease Activity Score for children with juvenile dermatomyositis: reliability and validity evidence. Arthritis Rheum 2003;49:715.
  • 12
    Charles PJ, Smeenk RJ, De Jong J, Feldman M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum 2000;43:238390.
  • 13
    Manna SK, Mukhopadhyay A, Aggarwal BB. IFN-α suppresses activation of nuclear transcription factors NF-κ B and activator protein 1 and potentiates TNF-induced apoptosis. J Immunol 2000;165:492734.
  • 14
    Iannone F, Scioscia C, Falappone P, Covelli M, Lapadula G. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 2006;33:18024.
  • 15
    Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Barbasso Helmers S, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008;67:16707.
  • 16
    Kim NN, Lio PA, Morgan GA, Jarvis JN, Pachman LM. Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis. Arch Dermatol 2011;147:8315.
  • 17
    Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al, and the RIM Study Group.Rituximab in the treatment of refractory adult and juvenile dermatomyositis: a randomized, placebo-phase trial. Arthritis Rheum 2013;65:31424.
  • 18
    Arabshahi B, Silverman RA, Jones OY, Rider RG. Abatacept and sodium thiosulfate for treatment of recalcitrant juvenile dermatomyositis complicated by ulceration and calcinosis. J Pediatr 2012;160:5202.